News Feature


Nature Biotechnology 25, 1379 - 1381 (2007)
doi:10.1038/nbt1207-1379

Hepatitis C: staying the course

Ken Garber1

  1. Ann Arbor, Michigan


A rash of failures for hepatitis C drugs, conflicting theories about the immune system's role and the looming issue of drug resistance make it impossible to predict when or how new therapies will make an impact. Ken Garber reports.

Top



Extra navigation

Subscribe to Nature Biotechnology

Subscribe

Search PubMed for

naturejobs

natureproducts


ADVERTISEMENT